Long Gao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Long Gao has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Wenbo Meng
Department of General Surgery, The First Hospital of Lanzhou University, No. 1 Donggang West Road, Lanzhou 730030, China
2 shared publications - Boru Jin
The First School of Clinical Medicine, Lanzhou University, Lanzhou 730030, China
1 shared publication Chong-Fei Huang
The First Clinical Medical College, Lanzhou University
1 shared publication- Dylan Lee
Curastrategix Health, USA
1 shared publication Hai-Dong Ma
The First Clinical Medical College, Lanzhou University
1 shared publication- Jian-Jun Chen
Lanzhou University
1 shared publication
Latest Publications
- Open Access
- 16 October 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (10) , 2356
Integrated Bile Metabolomics and Serum Biomarkers for Differentiating Cholangiocarcinoma from Cholelithiasis
Background: We investigated bile metabolites and serum variables for differentiating cholangiocarcinoma (CCA) from cholelithiasis. Methods: Bile from 31 patients with CCA and 48 with cholelithiasis was profiled by high-resolution LC-MS. Candidate metabolites and serum variables were integrated in a seven-variable classifier, and public single-cell data provided tissue-level biological context. Results: Of 2269 annotated metabolite features, 532 met the exploratory screening criteria. The selected signature comprised pyruvic acid, lipoxin A4, CEA, APOA1, 3-chloro-L-tyrosine, ADP-ribose, and glutaric acid; pyruvic acid had the largest contribution in the SHAP analysis. Random forest achieved an AUC of 0.894 in the classifier comparison, a training cross-validation AUC of 0.820, and an AUC of 0.914 in the 16-patient test subset. Because selection used all 79 patients before evaluation, these internal performance estimates may be optimistic. Conclusions: Integrated bile and serum profiling identified a promising seven-variable signature for differentiating CCA from cholelithiasis in this cohort. Added diagnostic value over routine serum markers and performance in other benign biliary conditions have not been established.
- 16 October 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (10) , 2356
Open AccessIntegrated Bile Metabolomics and Serum Biomarkers for Differentiating Cholangiocarcinoma from Cholelithiasis
Background: We investigated bile metabolites and serum variables for differentiating cholangiocarcinoma (CCA) from cholelithiasis. Methods: Bile from 31 patients with CCA and 48 with cholelithiasis was profiled by high-resolution LC-MS. Candidate metabolites and serum variables were integrated in a seven-variable classifier, and public single-cell data provided tissue-level biological context. Results: Of 2269 annotated metabolite features, 532 met the exploratory screening criteria. The selected signature comprised pyruvic acid, lipoxin A4, CEA, APOA1, 3-chloro-L-tyrosine, ADP-ribose, and glutaric acid; pyruvic acid had the largest contribution in the SHAP analysis. Random forest achieved an AUC of 0.894 in the classifier comparison, a training cross-validation AUC of 0.820, and an AUC of 0.914 in the 16-patient test subset. Because selection used all 79 patients before evaluation, these internal performance estimates may be optimistic. Conclusions: Integrated bile and serum profiling identified a promising seven-variable signature for differentiating CCA from cholelithiasis in this cohort. Added diagnostic value over routine serum markers and performance in other benign biliary conditions have not been established.
- Open Access
- 25 May 2026
- Published by Frontiers Media SA in Frontiers in Toxicology
- Vol. 8, 1783444
Evaluation and investigation of the cardiotoxicity of the potential anti-cholangiocarcinoma drug lanatoside C
Objective: Lanatoside C (Lan C), a cardiac glycoside, has demonstrated potent anti-cholangiocarcinoma activity. However, its potential cardiotoxicity at therapeutic doses remains poorly understood. This study aimed to systematically evaluate the cardiotoxicity of Lan C at cellular and organ levels and to elucidate its underlying molecular mechanisms. Methods: Human AC16 cardiomyocytes (ATCC® CRL-3568™) were employed for in vitro studies, with untreated cells included as negative controls. Cytotoxic effects at anti-cholangiocarcinoma-relevant concentrations (50–200 nM) were evaluated using a combination of cell viability assays, transmission electron microscopy, flow cytometry for apoptosis and reactive oxygen species (ROS) detection, JC-1 staining to assess mitochondrial membrane potential, lactate dehydrogenase (LDH) release assays, and Western blot analysis of apoptotic proteins. Male BALB/c mice were administered either vehicle (PBS) or Lan C (80 mg/kg/day) by oral gavage for 28 consecutive days. Cardiac function was assessed by echocardiography, and myocardial architecture was examined through histopathological analysis. Results: Lan C showed a dose-dependent inhibitory effect in vitro on AC16 cell viability and induced apoptosis. This process involved decreased mitochondrial membrane potential, increased reactive oxygen species (ROS), downregulation of the anti-apoptotic protein Bcl-2, and upregulation of cytochrome C, Cleaved Caspase-9, and Cleaved Caspase-3, indicating activation of the mitochondrial-dependent apoptotic pathway. In vivo , high-dose Lan C significantly impaired left ventricular systolic function, as indicated by reductions in LVEF and LVFS, and induced myocardial structural alterations. Conclusion: Lan C exhibits measurable but relatively low cardiotoxicity at concentrations effective against cholangiocarcinoma, with cardiac effects may be manageable at therapeutic doses. These findings support Lan C as a promising anti-tumor candidate with controllable cardiotoxicity under optimized dosing and clinical monitoring.
- 25 May 2026
- Published by Frontiers Media SA in Frontiers in Toxicology
- Vol. 8, 1783444
Open AccessEvaluation and investigation of the cardiotoxicity of the potential anti-cholangiocarcinoma drug lanatoside C
Objective: Lanatoside C (Lan C), a cardiac glycoside, has demonstrated potent anti-cholangiocarcinoma activity. However, its potential cardiotoxicity at therapeutic doses remains poorly understood. This study aimed to systematically evaluate the cardiotoxicity of Lan C at cellular and organ levels and to elucidate its underlying molecular mechanisms. Methods: Human AC16 cardiomyocytes (ATCC® CRL-3568™) were employed for in vitro studies, with untreated cells included as negative controls. Cytotoxic effects at anti-cholangiocarcinoma-relevant concentrations (50–200 nM) were evaluated using a combination of cell viability assays, transmission electron microscopy, flow cytometry for apoptosis and reactive oxygen species (ROS) detection, JC-1 staining to assess mitochondrial membrane potential, lactate dehydrogenase (LDH) release assays, and Western blot analysis of apoptotic proteins. Male BALB/c mice were administered either vehicle (PBS) or Lan C (80 mg/kg/day) by oral gavage for 28 consecutive days. Cardiac function was assessed by echocardiography, and myocardial architecture was examined through histopathological analysis. Results: Lan C showed a dose-dependent inhibitory effect in vitro on AC16 cell viability and induced apoptosis. This process involved decreased mitochondrial membrane potential, increased reactive oxygen species (ROS), downregulation of the anti-apoptotic protein Bcl-2, and upregulation of cytochrome C, Cleaved Caspase-9, and Cleaved Caspase-3, indicating activation of the mitochondrial-dependent apoptotic pathway. In vivo , high-dose Lan C significantly impaired left ventricular systolic function, as indicated by reductions in LVEF and LVFS, and induced myocardial structural alterations. Conclusion: Lan C exhibits measurable but relatively low cardiotoxicity at concentrations effective against cholangiocarcinoma, with cardiac effects may be manageable at therapeutic doses. These findings support Lan C as a promising anti-tumor candidate with controllable cardiotoxicity under optimized dosing and clinical monitoring.